SCHEMBL21646073

SCHEMBL21646073

O=C1CC(O)(Cc2ccccc2)C(=O)c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 5/20 0.43
KDM4E B2RXH2 3/20 0.43
APAF1 O14727 2/20 0.43
TDP2 O95551 2/20 0.43
NSD2 O96028 2/20 0.43
KDM4C Q9H3R0 1/20 0.43
ALDH1A1 P00352 6/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
ALOX12 P18054 1/20 0.42
CASP1 P29466 1/20 0.42
CA7 P43166 1/20 0.42
RECQL P46063 1/20 0.42
BACE1 P56817 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11208493 0.83 NPSR1 (0.66) HTTL3MBTL1NPSR1LMNAMAPT
SCHEMBL2724212 0.72 ALDH1A1 (0.54) HTTL3MBTL1NPSR1MAPTKDM4E
SCHEMBL25835313 0.70 ALDH1A1 (0.47) HTTL3MBTL1MAPTKDM4EAPAF1
SCHEMBL12822665 0.69 POLB (0.51) HTTL3MBTL1NPSR1LMNAMAPT
SCHEMBL25835259 0.69 POLB (0.51) HTTL3MBTL1NPSR1LMNAMAPT
SCHEMBL2956347 0.69 ALDH1A1 (0.50) HTTL3MBTL1NPSR1MAPTKDM4E
SCHEMBL8624780 0.69 CRBN (0.43) HTTL3MBTL1NPSR1LMNAMAPT
SCHEMBL17386423 0.68 HTT (0.43) HTTL3MBTL1NPSR1LMNAMAPT
SCHEMBL7760631 0.66 MEN1 (0.47) HTTL3MBTL1NPSR1LMNAMAPT
SCHEMBL28357232 0.66 MAPT (0.44) HTTL3MBTL1NPSR1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240041849-A1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2024-02-08 US disclosed
US-11771685-B2 Compounds for the treatment of neurological or mitochondrial diseases MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2023-10-03 US disclosed
US-20220125774-A1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2022-04-28 US disclosed
EP-3829560-A1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES Musc Foundation for Research Development (US) 2021-06-09 EP disclosed
CN-112770735-A Compounds for the treatment of neurological or mitochondrial diseases MUSC研究发展基金会 2021-05-07 CN disclosed
WO-2020028222-A1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2020-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041849-A1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES MT-ND2, MT-ND1, NLN HTT 225/4885L3MBTL1 1854/4885NPSR1 3346/4885
US-11771685-B2 Compounds for the treatment of neurological or mitochondrial diseases MT-ND2, MT-ND1, NLN HTT 225/4885L3MBTL1 1854/4885NPSR1 3346/4885
US-20220125774-A1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES MT-ND2, MT-ND1, NLN HTT 225/4885L3MBTL1 1854/4885NPSR1 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.